Showing 1 to 11 of 11 results
Lower-Cost HIV Prevention Drug to Reach Millions
A new, injectable HIV prevention drug, Lenacapavir, will be made available at a drastically reduced cost of $40 per year in over 120 low- and middle-income countries by 2027, potentially impacting millions and accelerating efforts to curb the HIV/AIDS epidemic.
Lower-Cost HIV Prevention Drug to Reach Millions
A new, injectable HIV prevention drug, Lenacapavir, will be made available at a drastically reduced cost of $40 per year in over 120 low- and middle-income countries by 2027, potentially impacting millions and accelerating efforts to curb the HIV/AIDS epidemic.
Progress
28% Bias Score
Trump Administration Considers Eliminating CDC's HIV Prevention Division
The Trump administration is considering eliminating the CDC's Division of HIV Prevention, potentially shifting its responsibilities to the HHS's Health Resources and Services Administration; this preliminary plan, facing resistance, could reverse progress in reducing HIV infections and cost millions...
Trump Administration Considers Eliminating CDC's HIV Prevention Division
The Trump administration is considering eliminating the CDC's Division of HIV Prevention, potentially shifting its responsibilities to the HHS's Health Resources and Services Administration; this preliminary plan, facing resistance, could reverse progress in reducing HIV infections and cost millions...
Progress
52% Bias Score
Male Circumcision Programs Reduce HIV Transmission in Sub-Saharan Africa
USAID's PEPFAR program has funded over 32.5 million voluntary medical male circumcisions since 2007, significantly reducing HIV transmission in countries like Mozambique, where over 2.5 million circumcisions were performed (2010-2023) with less than 2% of recipients becoming HIV-positive, proving a ...
Male Circumcision Programs Reduce HIV Transmission in Sub-Saharan Africa
USAID's PEPFAR program has funded over 32.5 million voluntary medical male circumcisions since 2007, significantly reducing HIV transmission in countries like Mozambique, where over 2.5 million circumcisions were performed (2010-2023) with less than 2% of recipients becoming HIV-positive, proving a ...
Progress
40% Bias Score
Lenacapavir: A Breakthrough HIV Drug Faces Access Challenges
A new injectable HIV drug, Lenacapavir, demonstrated a 96% reduction in infection risk in clinical trials, leading Science magazine to name it 'Discovery of the Year' for 2024; however, global access is hindered by high costs and limited distribution agreements.
Lenacapavir: A Breakthrough HIV Drug Faces Access Challenges
A new injectable HIV drug, Lenacapavir, demonstrated a 96% reduction in infection risk in clinical trials, leading Science magazine to name it 'Discovery of the Year' for 2024; however, global access is hindered by high costs and limited distribution agreements.
Progress
44% Bias Score
Lenacapavir: A Breakthrough in HIV Prevention
Two large clinical trials showed lenacapavir, a twice-yearly injection, to be 96–100% effective in preventing HIV, exceeding daily oral PrEP's real-world effectiveness; this breakthrough could significantly curb the global HIV epidemic, though access challenges remain.
Lenacapavir: A Breakthrough in HIV Prevention
Two large clinical trials showed lenacapavir, a twice-yearly injection, to be 96–100% effective in preventing HIV, exceeding daily oral PrEP's real-world effectiveness; this breakthrough could significantly curb the global HIV epidemic, though access challenges remain.
Progress
52% Bias Score
Injectable HIV PrEP Shows 96% Infection Reduction
Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.
Injectable HIV PrEP Shows 96% Infection Reduction
Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.
Progress
48% Bias Score
Spain's PrEP Program Expands to Pharmacies, Reaching 30,000 Users
Spain's PrEP (HIV pre-exposure prophylaxis) program, launched in November 2019, has reached 30,000 users, mostly LGBTQ+ individuals, and is transitioning to pharmacy distribution to improve access and integrate broader sexual health services, including STI testing and addressing chemsex.
Spain's PrEP Program Expands to Pharmacies, Reaching 30,000 Users
Spain's PrEP (HIV pre-exposure prophylaxis) program, launched in November 2019, has reached 30,000 users, mostly LGBTQ+ individuals, and is transitioning to pharmacy distribution to improve access and integrate broader sexual health services, including STI testing and addressing chemsex.
Progress
44% Bias Score
Trump's USAID Cuts Force Johns Hopkins to Eliminate Over 2,000 Jobs
Johns Hopkins University will eliminate over 2,000 jobs due to the Trump administration's rescission of more than $800 million in USAID funding for international health programs, impacting research, global health security, and the Baltimore economy.
Trump's USAID Cuts Force Johns Hopkins to Eliminate Over 2,000 Jobs
Johns Hopkins University will eliminate over 2,000 jobs due to the Trump administration's rescission of more than $800 million in USAID funding for international health programs, impacting research, global health security, and the Baltimore economy.
Progress
48% Bias Score
US Foreign Aid Freeze Cripples HIV Prevention in Lesotho, Triggers Global Job Losses
In Lesotho, the suspension of US foreign aid has halted HIV prevention programs, impacting hundreds of children and jeopardizing access to vital medication, resulting in widespread job losses within the USAID sector and causing uncertainty among international development professionals.
US Foreign Aid Freeze Cripples HIV Prevention in Lesotho, Triggers Global Job Losses
In Lesotho, the suspension of US foreign aid has halted HIV prevention programs, impacting hundreds of children and jeopardizing access to vital medication, resulting in widespread job losses within the USAID sector and causing uncertainty among international development professionals.
Progress
36% Bias Score
Lenacapavir: Science's 2024 Breakthrough in HIV Prevention
Science magazine named the injectable HIV prevention drug lenacapavir its 2024 breakthrough; 99.9% effective in preventing HIV in clinical trials among men who have sex with men and transgender individuals, offering a six-month dosage alternative to daily oral PrEP, pending FDA (2025) and European a...
Lenacapavir: Science's 2024 Breakthrough in HIV Prevention
Science magazine named the injectable HIV prevention drug lenacapavir its 2024 breakthrough; 99.9% effective in preventing HIV in clinical trials among men who have sex with men and transgender individuals, offering a six-month dosage alternative to daily oral PrEP, pending FDA (2025) and European a...
Progress
32% Bias Score
Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges
A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.
Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges
A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.
Progress
40% Bias Score
Showing 1 to 11 of 11 results